Skip to content

Press Releases

Recombinetics Announces Collaboration with Mayo Clinic to Develop the First-Ever Swine Models of Osteogenesis Imperfecta

October 7, 2019

Recombinetics today announced a collaborative research project with Mayo Clinic to advance Osteogenesis Imperfecta (OI) research by developing the first-ever swine models of OI. These models will help preclinical researchers better understand disease etiology and progression and provide a reliable preclinical model for establishing the safety and efficacy of new therapies that patients with OI…

Read More

Recombinetics Awarded National Institutes of Health Funding to Develop Genetically Engineered Swine Model of Glioblastoma, the Deadliest Type of Brain Tumor

July 17, 2019

In honor of Glioblastoma Awareness Day (#GBMDay), Recombinetics today announced it has received a grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to fund the development of a novel genetically engineered swine model of glioblastoma, the most common and aggressive malignant primary brain tumor. If successful, this model…

Read More

The Alliance to End Surgical Castration of Swine Announces Precision Breeding Successes

June 19, 2019

Multiple healthy litters of naturally castrated piglets developed through precision breeding Male piglets are routinely castrated to improve the quality of meat for consumers by eliminating boar taint, an unpleasant odor, and unsavory taste. This practice is an animal well-being concern and is being banned in the European Union. In April 2018, pioneering companies in…

Read More

Acceligen and Kheiron-Biotech Announce Joint Projects Focused on Precision Breeding

June 18, 2019

Project Aims to Introduce New Commercial Traits in Cattle Derived from Elite Genetic Lines Acceligen, a Recombinetics company, and Kheiron-Biotech, a Proinvesa Group company, are teaming up on a series of projects in Argentina that intends to produce multiple animal product lines to solve existing concerns in the cattle industries. These combined efforts will leverage…

Read More

Recombinetics Names Dr. Tad Sonstegard the First Chief Executive Officer of Its Wholly-Owned Subsidiary, Acceligen

May 29, 2019

Today, Recombinetics named Dr. Tad Sonstegard the first Chief Executive Officer of its wholly-owned subsidiary, Acceligen.  Sonstegard will lead Acceligen’s efforts to raise capital and strategic partnerships for its products that genetically improve the health and well-being of livestock and aquaculture. With Acceligen now entering into significant commercial transactions, Sonstegard’s leadership will ensure that Acceligen…

Read More

Medical Alley Q3 Breakdown: All Major Sectors in Medical Alley Break $100 Million Raised for First Time

November 12, 2018
Read More

Recombinetics Announces Collaboration with Mayo Clinic to Grow Human Cardiomyocytes in Swine for Exo-transplantation

October 17, 2018

Recombinetics today announced a multi-project, collaborative research and development agreement with Mayo Clinic to advance capabilities to bioengineer human stem cells within swine models. The collaboration is focused on utilizing human stem cells to produce human tissue products in a surrogate pig for exo-transplantation back into humans. These regenerative stem cell therapies aim to provide…

Read More

Recombinetics Launches TARGET-TB with Researchers in the Republic of Ireland and Northern Ireland to Develop Genome Editing Solutions for Bovine Tuberculosis

October 5, 2018

Research aims to reduce the public health risk and financial costs associated with this disease Recombinetics announced today the launch of TARGET-TB, a tripartite collaborative research project with University College Dublin in the Republic of Ireland and Queen’s University Belfast in Northern Ireland to combat Mycobacterium bovis (M. bovis) infection, the pathogen that causes bovine…

Read More

Recombinetics Announces New Board of Directors with Representatives from a Series A Strategic Investor: Gundersen Health System

August 24, 2018

Recombinetics today announced its new board of directors following this week’s completion of a $34 million Series A financing round. Gundersen Health System, a physician-led, not-for-profit healthcare system with locations in Wisconsin, Minnesota and Iowa, led the round as a strategic investor and now has three representatives on Recombinetics’ Board. Following the first meeting of…

Read More